Jaspal Kaeda

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Timothy P. Hughes, Jaspal Kaeda, Susan Branford et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

Life Sciences, Hematology, Oncology +13

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad et al. · Journal of Clinical Oncology · 2008 · 556 citations

Medicine, Hematology, Pharmacology +8

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford et al. · Blood · 2010 · 487 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

David Marín, Dragana Milojković, Eduardo Olavarría et al. · Blood · 2008 · 328 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia

Francesco Dazzi, Richard Szydlo, Charles Craddock et al. · Blood · 2000 · 295 citations · Full text

Life Sciences, Hematology, Immunology +15